Gynecologic Cancer
Leadership
Program Overview
Recent discoveries in genetics and genomics hold great promise for the development of target-defined prevention and chemotherapeutic strategies for gynecological cancers.
However, a coordinated, multi-disciplinary research effort is required to translate these new research discoveries into the next generation of therapeutic strategies.
To meet this challenge the Gynecologic Cancer Research Program aims to:
- Define early events in gyncologic carcinogenesis
- Translate these advances into targeted therapeutic approaches for the prevention and treatment of gynecologic cancer
- Test these new therapies in investigator-initiated and multi-institutional clinical trials
Since its inception, the program has successfully fostered scientific interactions between members of the Duke Cancer Institute who have basic, translational, and clinical research interests in gynecologic cancer.
Within the domain of the program we developed five subprograms that draw from our translational research strength and ability to translate basic science discoveries to impact the early detection and treatment of gynecologic cancer:
- Early detection strategies for gynecologic cancer
- Methylation imprinting and epigenetic dysregulation
- Basic gynecologic cancer biology and novel therapeutic targeting
- Genomics
- Disparities for African American women
The diversity of interest and experimental approaches used by the members of the Gynecologic Cancer Research Program represents an effective environment for fostering cross-fertilization of ideas aimed at understanding gynecologic cancer. In addition, the Program supports developmental projects, new faculty awards, and tissue procurement and banking.
